Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)

Mineralys Therapeutics is launching lorundrostat as a second-to-market ASI, with limited efficacy or safety differentiation from BAXFENDY and barriers from AstraZeneca's established franchise and restrictive payer policies. Peak sales are modeled at approximately $800 million; the analyst considers MLYS fairly valued and upgrades the rating from Sell to Hold.

Analysis

The key valuation variable is not launch awareness but whether lorundrostat earns a usable place in the treatment pathway: restrictive coverage or step edits can cap treated-patient conversion and net revenue even if physician interest is real. Early prescription data alone may therefore overstate commercial traction; prioritize payer coverage, time-to-approval, discontinuation, and refill persistence. AstraZeneca’s established cardiorenal presence is a competitive constraint, though any benefit to AZN is likely immaterial relative to its broader portfolio unless the new entrant changes category pricing or treatment sequencing.

Over the next 1–3 months, payer decisions and launch-quality indicators matter more than the headline peak-sales estimate. Over 6–18 months, the thesis turns on whether clinical or real-world evidence establishes a meaningful subgroup advantage that can overcome step therapy. The contrarian upside is that a second entrant could validate the mechanism and broaden physician familiarity; that is not yet evidence of share capture. Conversely, the Hold view can fail on either side: unexpectedly broad access and durable use could make current expectations conservative, while persistent access friction or weak refill behavior would undermine the modeled opportunity. Verify cash runway and launch economics before assigning additional balance-sheet or dilution risk.

Key Decisions for Investors

• MLYS: Keep at Hold / market weight rather than add ahead of access evidence. Treat launch announcements and initial script counts as low-quality signals until payer coverage, approval timing, and refill persistence are visible.
• Catalyst watch for the next 1–3 months: track formulary placement, step-therapy requirements, and management’s launch commentary. Broad access with improving persistence would challenge the cautious view; restrictive coverage or weak conversion would strengthen it.
• Avoid using AZN as a direct hedge for MLYS: AZN’s broad portfolio makes the competitive exposure comparatively diluted. Reassess any relative-value trade only if evidence shows lorundrostat is taking measurable share from an AZN product or changing category economics.
• Falsification triggers: upgrade the MLYS view if access and repeat use materially exceed expectations or evidence supports a differentiated patient segment; reconsider exposure if payer barriers persist, launch indicators fail to convert into durable use, or verified cash-runway data raises financing concerns.